A clinical trial has demonstrated that LPA levels are markedly increased in patients with idiopathic pulmonary fibrosis, and that the suppression of LPA1 markedly attenuates the chemotactic effects on the fibroblasts in this fluid [15] (Figure 3). The gene discussed is LPAR1; the disease is idiopathic pulmonary fibrosis.